Epithelial–mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure

Prostate cancer progression is concomitant with quantifiable nuclear structure and texture changes as compared to non‐cancer tissue. Malignant progression is associated with an epithelial–mesenchymal transition (EMT) program whereby epithelial cancer cells take on a mesenchymal phenotype and dissociate from a tumor mass, invade, and disseminate to distant metastatic sites. The objective of this study was to determine if epithelial and mesenchymal prostate cancer cells have different nuclear morphology.

[1]  Kristian Helin,et al.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.

[2]  A. Partin,et al.  Pro–Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer , 2009, Clinical Cancer Research.

[3]  Robert W Veltri,et al.  Nuclear morphometry, nucleomics and prostate cancer progression. , 2012, Asian journal of andrology.

[4]  Peter Teague,et al.  Differences in the Localization and Morphology of Chromosomes in the Human Nucleus , 1999, The Journal of cell biology.

[5]  Cameron S. Osborne,et al.  Active genes dynamically colocalize to shared sites of ongoing transcription , 2004, Nature Genetics.

[6]  P. McCue,et al.  Molecular diagnosis of prostate cancer: are we up to age? , 2013, Seminars in oncology.

[7]  G. Moreno-Bueno,et al.  Correlation of Snail expression with histological grade and lymph node status in breast carcinomas , 2002, Oncogene.

[8]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[9]  Rohit Bhargava,et al.  Nuclear nano-morphology markers of histologically normal cells detect the “field effect” of breast cancer , 2012, Breast Cancer Research and Treatment.

[10]  Mark D. Robinson,et al.  Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity , 2010, Nature Cell Biology.

[11]  T. Kwast.  Prognostic prostate tissue biomarkers of potential clinical use , 2014, Virchows Archiv.

[12]  K. Pantel,et al.  Plasticity of disseminating cancer cells in patients with epithelial malignancies , 2012, Cancer and Metastasis Reviews.

[13]  A. Puisieux,et al.  Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.

[14]  Angus I. Lamond,et al.  Spatial Organization of Large-Scale Chromatin Domains in the Nucleus: A Magnified View of Single Chromosome Territories , 1997, The Journal of cell biology.

[15]  Alan Wells,et al.  Partial Mesenchymal to Epithelial Reverting Transition in Breast and Prostate Cancer Metastases , 2012, Cancer Microenvironment.

[16]  Jonathan I. Epstein,et al.  Ability to Predict Metastasis Based On Pathology Findings and Alterations in Nuclear Structure Of Normal-Appearing and Cancer Peripheral Zone Epithelium in the Prostate , 2004, Clinical Cancer Research.

[17]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[18]  B. Teh,et al.  Methylation Subtypes and Large-Scale Epigenetic Alterations in Gastric Cancer , 2012, Science Translational Medicine.

[19]  Anant Madabhushi,et al.  Adaptive Energy Selective Active Contour with Shape Priors for Nuclear Segmentation and Gleason Grading of Prostate Cancer , 2011, MICCAI.

[20]  Thomas Cremer,et al.  Nuclear Organization of Mammalian Genomes , 1999, The Journal of cell biology.

[21]  Kenneth M. Yamada,et al.  The Zinc-finger Protein Slug Causes Desmosome Dissociation, an Initial and Necessary Step for Growth Factor–induced Epithelial–mesenchymal Transition , 1997 .

[22]  J. Epstein,et al.  Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer , 1984, Cancer.

[23]  B. Tombal,et al.  Can we improve the definition of high‐risk, hormone naïve, non‐metastatic prostate cancer? , 2014, BJU international.

[24]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[25]  Wai Leong Tam,et al.  The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.

[26]  Richard C. McEachin,et al.  Transcription Factors OVOL1 and OVOL2 Induce the Mesenchymal to Epithelial Transition in Human Cancer , 2013, PloS one.

[27]  Daniele Zink,et al.  Nuclear structure in cancer cells , 2004, Nature Reviews Cancer.

[28]  Anup Amatya,et al.  Development of a Nuclear Morphometric Signature for Prostate Cancer Risk in Negative Biopsies , 2013, PloS one.

[29]  D. Saur,et al.  E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. , 2009, Gastroenterology.

[30]  Robert W Veltri,et al.  Nuclear Morphometry, Epigenetic Changes, and Clinical Relevance in Prostate Cancer , 2013, Advances in experimental medicine and biology.

[31]  A. Partin,et al.  Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis , 2007, The Prostate.

[32]  A W Partin,et al.  Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections. , 1988, The Journal of urology.

[33]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[34]  A W Partin,et al.  Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system. , 1988, The Journal of urology.

[35]  A. Partin,et al.  Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease‐free survival among patients with prostate cancer , 1992, Cancer.

[36]  E. Ballestar,et al.  Snail Mediates E-Cadherin Repression by the Recruitment of the Sin3A/Histone Deacetylase 1 (HDAC1)/HDAC2 Complex , 2004, Molecular and Cellular Biology.

[37]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[38]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[39]  Julia Schüler,et al.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs , 2009, Nature Cell Biology.